Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347052 | 0.86 | CYP2A6 (0.54) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL5276252 | 0.84 | MAPT (0.68) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL5276244 | 0.84 | MAPT (0.68) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL30209646 | 0.84 | MAPT (0.68) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL787960 | 0.84 | CYP2A6 (0.59) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL7773883 | 0.80 | CYP2A6 (0.54) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL8739807 | 0.78 | CYP2A6 (0.53) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL25001258 | 0.76 | APP (0.58) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL15486685 | 0.76 | MEN1 (0.77) | CYP2A6IMPDH2ALDH1A1ATMHPGD | |
| SCHEMBL531504 | 0.76 | MEN1 (0.77) | CYP2A6IMPDH2ALDH1A1ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | CYP2A6 1102/4885IMPDH2 1795/4885ALDH1A1 451/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | CYP2A6 158/4885IMPDH2 2419/4885ALDH1A1 58/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | CYP2A6 3101/4885IMPDH2 2915/4885ALDH1A1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.